Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAMM 4: GSK2857916 in combination with pembrolizumab in relapsed/refractory multiple myeloma
2018-002816-29Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belantamab mafodotin and pembrolizumab in multiple myeloma (MM), sponsored by GSK. Primary endpoints: Safety and tolerability (Part 1) and Clinical activity (Part 1). Started Feb 2019; status: completed.
02
Drugs
belantamab mafodotinpembrolizumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2018-002816-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002816-29.